Chief Medical Officer · Larimar Therapeutics, Inc. (LRMR)

Dennis Kim

A named executive officer of Larimar Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,285,090

Salary $409,000Stock awards $0

FY2017: $785,802

4th of 4 named executive officers at Larimar Therapeutics by FY2018 total.

4 named officers on file for Larimar Therapeutics, FY2018

Dennis Kim’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Larimar Therapeutics’s whole pay program stands against its peers

  • Larimar Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LRMR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2019 (DEF 14A).

Free

Get Dennis Kim’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Dennis Kim compensation by year

Larimar Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Larimar Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$392,000$409,000
Bonus$0$0
Stock awards$0$0
Option awards$261,492$781,950
Non-equity incentive$126,910$85,890
Pension and deferred compensation$0$0
All other$5,400$8,250
Total$785,802$1,285,090

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Larimar Therapeutics, Inc. DEF 14A filed April 26, 2019, accession 0001193125-19-122675, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Larimar Therapeutics, Inc. filed document, accession 0001193125-19-122675. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2019.

$786K
$1.3M
FY17
FY18
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option3,750—$38.65
Option23,438—$6.68
Option45,834—$4.05
Option125,000—$7.77

Per the Outstanding Equity Awards at Fiscal Year-End table in Larimar Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Larimar Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Jeffrey HatfieldChief Executive Officer$2,468,855
Thomas HughesPresident and Chief Scientific Officer$2,096,341
Brian McVeighChief Business Officer$1,462,930
Dennis Kim · this pageChief Medical Officer$1,285,090

The full Larimar Therapeutics compensation record

free company brief

This page is one person within Larimar Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Larimar Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Dennis Kim's compensation dossier · One-time report. No refunds.